当代腔内治疗时代破裂腹主动脉瘤的短期与中期生存
本研究在拥有43家医院和四级转诊中心的系统中回顾性分析了2012至2017年因腹主动脉瘤急诊治疗的249例患者,其中102例(41%)接受急诊治疗。Kaplan-Meier估计全部患者30天和1年生存率分别为64%和53%,破裂患者为58%和46%,症状性患者为86%和81%。EVAR较开放修复改善了30天生存(64% vs 31%;比值比4.0;P = .03)和1年生存(40% vs 23%;比值比2.3;P = .4)。
要点
- 全部急诊治疗患者30天和1年生存率分别为64%和53%。
- 破裂患者30天和1年生存率分别为58%和46%,症状性患者为86%和81%。
- EVAR较开放修复改善30天生存(64% vs 31%;比值比4.0;P = .03)。
核心结论
- EVAR与开放修复相比可改善需急诊腹主动脉瘤修复患者的生存。
- 但第一年内基于初始表现和基础合并症存在显著死亡风险。
- 为改善长期生存,作者认为积极的内科管理和医学监测是必要的。
研究设计与样本
- 回顾性分析2012年至2017年间在机构审查委员会批准的登记中前瞻性捕获的急诊腹主动脉瘤治疗患者。
- 共249例患者作为方案的一部分被转诊,其中102例(41%)接受急诊治疗。
- 主要结局为全部组以及症状性和破裂动脉瘤的30天死亡率和1年生存率。
- 采用逻辑回归生存曲线分析,并进行log-rank检验比较开放与腔内修复的生存。
- 按意向治疗原则评估患者,并在多变量模型中评估结局。
主要发现
- Kaplan-Meier估计全部患者30天和1年生存率分别为64%和53%,破裂患者为58%和46%,症状性患者为86%和81%。
- EVAR较开放修复改善30天生存(64% vs 31%;比值比4.0;P = .03)。
- EVAR较开放修复1年生存为40% vs 23%(比值比2.3;P = .4)。
- 30天死亡率的显著预测因素包括低血压(P = .0003)、输血(P < .0001)、住院时间(P = .0005)、造影剂外渗(P = .01)、术前心肺复苏(P = .04)、开放修复(P = .007)、主-单髂动脉重建(P = .008)和腹腔间隔室综合征(P = .007)。
- 1年死亡率的显著预测因素包括高龄(P = .04)、低血压(P = .01)、输血(P = .006)、造影剂外渗(P = .03)、再插管(P = .03)和腹腔间隔室综合征(P = .03)。
临床怎么用
- 作者认为,为改善长期生存,积极的内科管理和医学监测是必要的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Endovascular aneurysm repair (EVAR) has been shown to reduce mortality in the emergent repair of ruptured abdominal aortic aneurysms (AAAs). However, long-term survival data for this group of patients are lacking with contemporary endovascular endografts. The purpose of this study was to evaluate both 30-day mortality rates and 1-year survival in patients undergoing emergent EVAR in a 43-facility hospital system with a quaternary referral center with an established ruptured aneurysm protocol. METHODS: Retrospective analysis of patients captured prospectively in an Institutional Review Board-approved registry for patients treated emergently for AAA were reviewed between 2012 and 2017 was conducted. Primary outcome measures were 30-day mortality and 1-year survival for the entire group as well as for symptomatic and ruptured aneurysms. Data were analyzed using logistic regression survival curves, and a log-rank test was performed to compare survival between open and endovascular repair. Patients were evaluated on an intent-to-treat basis, and outcomes were evaluated in a multivariate model. RESULTS: A total of 249 patients were referred as part of the protocol. Of these, 102 (41%) were treated emergently. Kaplan-Meier estimates of 30-day and 1-year survival were 64% and 53% for all patients, 58% and 46% for ruptured patients, and 86% and 81% for symptomatic patients. EVAR resulted in improved 30-day survival (64% vs 31%; odds ratio, 4.0; P = .03) and 1-year survival (40% vs 23%; odds ratio, 2.3; P = .4) over open repair. Significant predictors for 30-day mortality included hypotension (P = .0003), blood transfusion (P < .0001), length of stay (P = .0005), extravasation (P = .01), preoperative cardiopulmonary resuscitation (P = .04), open repair (P = .007), aortouni-iliac reconstruction (P = .008), and abdominal compartment syndrome (P = .007). Significant predictors for 1-year mortality included advanced age (P = .04), hypotension (P = .01), blood transfusion (P = .006), extravasation (P = .03), reintubation (P = .03), and abdominal compartment syndrome (P = .03). There were no differences in outcomes based on race, gender, or outside transfer. Peripheral arterial disease (P = .04), hypertension (P = .04), coronary artery disease (P = .03), and familial history of aneurysms (P = .05) were related to increased 30-day mortality. Peripheral arterial disease (P = .06) and coronary artery disease (P = .07) were nearly significant, with increased 1-year mortality. CONCLUSIONS: EVAR is associated with improved survival compared with open repair in patients requiring emergent AAA repair. However, in the first year, there is a significant risk of death based on initial presentation as well as underlying comorbidities. To improve long-term survival, aggressive medical management and medical surveillance are warranted.
引用
- Briggs CS, Sibille JA, Yammine H, et al. Short-term and midterm survival of ruptured abdominal aortic aneurysms in the contemporary endovascular era. J Vasc Surg. 2018. PMID: 29526377. doi:10.1016/j.jvs.2017.12.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。